# Jaguar Gene Therapy

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/jaguar-gene-therapy

- Industry: Biotechnology
- Headquarters: Lake Forest, US
- Website: www.jaguargenetherapy.com
- Total disclosed funding: $139M
- Latest round: Series B (Apr 13, 2021)
- Investors on record: 5

## About

Jaguar Gene Therapy, LLC, based in the US, focuses on developing advanced gene therapies to treat severe genetic diseases, utilizing a specialized AAV gene therapy platform to address underlying health issues.Founded in 2019 and headquartered in Lake Forest, US, Jaguar Gene Therapy, LLC specializes in innovative gene therapy solutions. The company has completed 4 deals, with the most recent funding round occurring on 2024-06-01, raising KRW 20,000.000 from investors including JDRF T1D Fund and Samsung Venture Investment. The CEO is Joseph Nolan.Jaguar Gene Therapy specializes in developing advanced gene therapies to treat severe genetic diseases, leveraging a well-characterized adeno-associated virus (AAV) gene therapy platform. Their portfolio includes therapies designed for one-time administration, improving patient lives with significant unmet needs. These therapies are scalable and commercially viable, targeting patient populations across North America, Europe, and parts of Asia. The company employs rigorous scientific development and next-generation technologies to transform treatment options for patients with debilitating genetic disorders.Jaguar Gene Therapy's revenue model is built on direct partnerships with healthcare providers, academic institutions, and regulatory bodies for the development and market distribution of their gene therapy products. They focus on navigating the complexities of the gene therapy landscape through collaborative efforts, ensuring rapid regulatory approvals. The company utilizes a B2B model to provide treatments through partnerships with hospitals and specialized clinics, emphasizing product purity and patient safety without disclosing specific pricing details.Jaguar Gene Therapy plans to expand its product offerings by designing and launching new gene therapies, with a focus on increasing accessibility to their innovative treatments. The company is targeting expansion into new markets, particularly in Europe and Asia, by 2025. Recent funding from the undisclosed amount raised in June 2024 will support these initiatives, enabling further development of therapies and facilitating entry into additional geographic regions.

## Funding rounds

- Series B, Apr 13, 2021, $139M — ARCH Venture Partners, Goldman Sachs Asset Management, Eli Lilly & Company, Deerfield Management, Nolan Capital
- Series A, Feb 25, 2021 — Deerfield Management

## Investors

- Deerfield Management (https://capitalatlas.ai/funds/deerfield-management) — Series A, Series B
- ARCH Venture Partners (https://capitalatlas.ai/funds/arch-venture-partners) — Series B
- Goldman Sachs Asset Management (https://capitalatlas.ai/funds/goldman-sachs-asset-management) — Series B
- Eli Lilly & Company — Series B
- Nolan Capital — Series B